TAT-10: Bi-213-anti-EGFR-Mab Therapy of Recurrent Bladder Cancer - A Pilot Study
These patients all had non-muscle invasive tumors that did not respond to BCG. A single dose of 366-821 MBq of Bi-213-EGFR-Mab was administered directly into the bladder by catheter. The bladder was drained 2 hours after injection.
All patients showed excellent tolerance with no side effects. Efficacy was determined by endoscopy and histology. Three patients showed complete eradication of tumor cells and 10 patients experienced tumor progression.
A follow-on study is planned with higher doses and repeat treatments.
Presented By: Klemens Scheidhauer from Department of Nuclear Medicine, Technische Universitaet Muenchen, Munich, Germany
Written By: William Carithers, Lawrence Berkeley National Laboratory
at the 10th International Symposium on Targeted Alpha Therapy (TAT-10) May 31 - June 1, 2017 - Kanazawa, Japan.